Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 9
Submit an article Journal homepage
26
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Investigational pharmacologic treatment for liver disease

Lori L Siatkosky Department of Pharmacy, Spectrum Health, Grand Rapids, MI, USA
,
Kenneth M Shermock Department of Pharmacy, The Cleveland Clinic Foundation, Cleveland, OH, USA
&
Zobair M Younossi Department of Pharmacy, The Cleveland Clinic Foundation, Cleveland, OH, USA
Pages 1281-1293 | Published online: 24 Feb 2005

Bibliography

  • RAEBEL MA, PALMER SM: Viral hepatitis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (Eds), Pharmacotherapy: a pathophysiologic approach. 4th edn. Appleton & Lange, Connecticut, USA. (1999):649–675.
  • COLACINO JM, STASCHKE KA: The identification and development of antiviral agents for the treatment of chronic hepatitis B infection. Frog. Drug Res. (1998) 50:259–322.
  • LOK AS, HEATHCOTE EJ, HOOFNAGLE JH: Management of Hepatitis B: 2000 - Summary of a workshop. Gastroenterology (2001) 120: 1828-1853.
  • •Good review of the treatment of hepatitis B with mention of new treatments.
  • LOK ASF, MCMAHON BJ: Chronic hepatitis B. Hepatology (2001) 34:1225–1241.
  • •Treatment guidelines for hepatitis B from the American Association for the Study of Liver Diseases.
  • YOUNOSSI Z: Viral hepatitis: a guide to practicing clinician. CCJM (2000) 67 (Supplement):S1–S48.
  • GORDON SC: Treatment of viral hepatitis. Ann. Med. (2001) 33:385–90.
  • HOOFNAGLE JH, DIBISCEGLIE AM: The treatment of chronic viral hepatitis. N Engl. J. Med. (1997) 336:347–356.
  • GERVAIS A, BOYER N, MARCELLIN P: Tolerability of treatment for viral hepatitis. Drug Safety (2001) 24:375–384.
  • DE CLERCG E: Antiviral drugs: current state of the art. J. Clin. Vir. (2001) 22:73–89.
  • ZOULIM F, TREPO C: New antiviral agents for the therapy of chronic hepatitis B virus infection. Intervirology (1999) 42:125–144.
  • HANTZ 0, KRAUS JL, ZOULIM F: Design and evaluation of hepatitis B virus inhibitors. Curt: Phartn. Des. (2000) 6:503–523.
  • FARRELL GC: Clinical potential of emerging new agents in hepatitis B. Drugs (2000) 60:701–710.
  • ONO-NITA SK, KATO N, SHIRATORI Y et al.: Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. Clin. Invest. (1999) 103:1635–1640.
  • BARDITCH-CROVO P, TOOLE J, HENDRIX CW et al.: Anti-human immunodeficiency virus (HIV) activity, safety and pharmacokinetics of adefovir dipivoxil (942-(bis-pivaloyloxymethyl)-phosphonylmethoxyethylladenine) in HIV-infected patients. J. Infect. Dis. (1997) 176:406–413.
  • CUNDY KC, BARDITCH-CROVO P, WALKER RE et al: Clinical pharmacokinetics of adefovir in human immunodeficiency virus Type 1-infected patients. Antimicrob. Agents Chemother. (1995) 39:2401–2405.
  • HUTCHISON TA, SHAHAN DR (Eds): DRUGDEX® System. MICROMEDEX (Volume 112), Greenwood Village, Colorado, USA. [Expires June 2002].
  • KAHN J, LAGAKOS S, WULFSOHN M et al.:Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. JAMA (1999) 282:2305–2312.
  • DEEKS SG, COLLIER A, LALEZARI J et al:The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: A randomized, double-blind, placebo-controlled trial. J. Infect. Dis. (1997) 176:1517–1523.
  • CULLEN JM, LI DH, BROWN C et al: Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. (2001) 45:2740–2745.
  • HEATHCOTE EJ, JEFFERS L, WRIGHT T et al.: Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled Phase II studies (abstract). Hepatology (1998) 28:317A.
  • PERRILLO R, SCHIFF E, YOSHIDA E et al.: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology (2000) 32:129–134.
  • BENHAMOU Y, BOCHET M, THIBAULT V et al.: Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 358:718–723.
  • WALSH KM, WOODALL T, LAMY P, WIGHT DGD, BLOOR S, ALEXANDER GJM: Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut (2001) 49:436–440.
  • MOLINA JM, FERCHAL F, RANCINAN C et al.: Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J. Infect. Dis. (2000) 182:599–602.
  • KORBA BE, SCHINAZI RE COTE P, TENNANT BC, GERIN JL: Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. (2000) 44:1757–1760.
  • WITCHER JW, BOUDINOT FD, BALDWIN BH et al.: Pharmacokinetics of 1-(2-fluoro-5-methyl L arabinofuranosyl) uracil in woodchucks. Ant-liana-ob. Agents Chemother. (1997) 41:2184–2187.
  • PAI SB, LIU SH, ZHU YL, CHU CK, CHENG YC: Inhibition of HBV by a novel L-nucleoside, 2'-fluoro-5-methyl L arabinofuranosyl uracil. Ant-nano-ob. Agents Chemother. (1996) 40:380–386.
  • CHIN R, SHAW T, TORRESI J et al: Invitro susceptibilities of wild-type or drug-resistant HBV to ( ) D 2,6 diaminopurine dioxolane and 2'-fluoro-5-methyl L arabinofuranosyluracil. Antimicrob. Agents Chemother. (2001) 45:2495–2501.
  • AGUESSE-GERMON S, LIU SH, CHEVALLIER M et al: Inhibitory effect of 2'-fluoro-5-methyl L arabinofuranosyl uracil on duck hepatitis B replication. Ant-nano-ob. Agents Chemother: (1998) 42:369–376.
  • PEEK SF, COTE PJ, JACOB JR et al.: Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl L arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Mannota mortax). Hepatology (2001) 33:254–266.
  • YAMANAKA G, WILSON T, INNAIMO S et al.: Metabolic studies on BMS-200475, a new antiviral compound active against HBV. Ant-nano-ob. Agents Chemother: (1999) 43:190–193.
  • INNAIMO SF, SEIFER M, BISACCHI GS, STANDRING DN, ZAHLER R, COLONNO RJ: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. (1997) 41:1444–1448.
  • MARION PL, SALAZAR FH, WINTERS MA, COLONNO RJ: Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob. Agents Chemother. (2002) 46:82–88.
  • COLONNO RJ, GENOVESI EV, MEDINA I et al: Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. Infect. Dis. (2001) 184:1236–1245.
  • DE MAN RA, WOLTERS LMM, NEVENS F et al.: Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 34:578–582.
  • CORBETT AH, RUBLEIN JC: DAPD (Emory University/Triangle Pharmaceuticals/ Abbott Laboratories). Carr: Opin. Invest. Drugs (2001) 2:348–353.
  • CHEN H, SCHINAZI RE RAJAGOPALAN P et al: Pharmacokinetics of (-)-13-D-dioxolane guanine and prodrug ( )D 2,6 diaminopurine dioxolane in ratsand monkeys. AIDS Res. Hum. Remo viruses (1999) 15:1625–1630.
  • SHAD JA, MCHUTCHISON JG: Current and future therapies of hepatitis C. OM. Liver Dis. (2001) 5:355–359.
  • BALFOUR HH: Antiviral drugs. N Engl. Med. (1999) 340:1255–1268.
  • PEPINSKY RB, LEPAGE DJ, GILL A et al.: Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-3-1a with preserved M vitro bioactivity. Pharmacol Exp. Ther. (2001) 297:1059–1066.
  • FRIED MW: Advances in therapy for chronic hepatitis C. Clin. Liver Dis. (2001) 5:1009–1023.
  • REDDY KJ: Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs. Ann. Pharmacother: (2000) 34:915–923.
  • •Good introduction to pegylating molecules.
  • BARNARD DL: Pegasys. Carr. Opin. Invest. Drugs (2001) 2:1530–1538.
  • •Good overview of peginterferon alfa-2a.
  • PEG-Intron package insert. Kenilworth, NJ: Schering Corporation; 2001 Aug.
  • ZEUZEM S, FEINMAN SV, RASENACK J et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl. I Med. (2000) 343:1666–1672.
  • ••Well-designed randomised, controlled trialfor peginterferon alfa-2a.
  • HEATHCOTE EJ, SHIFFMAN ML, COOKSLEY GE et al: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl. I Med. (2000) 343:1673–1680.
  • ••Well-designed randomised, controlled trial trial for peginterferon alfa-2a.
  • GLUE P, FANG JWS, ROUZIER-PANIS R et al: Pegylated interferon-a2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol Ther. (2000) 68:556–567.
  • LINDSAY KL, TREPO C, HEINTGES T et al.: A randomized, double-blind trial comparing pegylated interferon alfa-26 to interferon alfa-26 as initial treatment for chronic hepatitis C. Hepatology (2001) 34:395–403.
  • ••Randomised, controlled trial comparingpeginterferon alfa-2b to interferon alfa–2b.
  • MANNS MP, MCHUTCHISON JG, GORDON SC et al.: Peginterferon alfa-26 plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 358:958–965.
  • ••Randomised, controlled trial to determineefficacy of the combination of peginterferon alfa-2b plus ribavirin.
  • PERRY CM, JARVIS B: Peginterferon-a-2a (40kD): A review of its use in the management of chronic hepatitis C. Drugs (2001) 61:2263–2288.
  • FRIED MW, SHIFFMAN ML, REDDY RK Pegylated (40kDa) intereron alfa-2a (PEGASYSO) in combination with ribavirin: Efficacy and safety results from a Phase III, randomized, actively-controlled multicenter study (abstract). Gastroenterology (2001) 120(Suppl.):A–55.
  • YOUNOSSI ZM, DIEHL AM, ONG JP: Nonalcoholic fatty liver disease: An agenda for clinical research. Hepatology (2002) 35:746–752.
  • •Good overview of non-alcoholic fatty liver disease.
  • YOUNOSSI Z: Non-Alcoholic Fatty Liver Disease: A Review. CurcGastroenterol Reports (1999) 1:57–62.
  • MATTEONI C, YOUNOSSI Z, GRAMLICH T, BOPARAI N, LIU Y, MCCULLOUGH A: Nonalcoholic fatty liver disease: a spectrum of clinical and pathologic severity. Gastroenterology (1999) 116:1413–1419.
  • LEE YM, KAPLAN MM: Primary sclerosingcholangitis. N Engl.' Med. (1995) 332:924–933.
  • Actigall package insert. East Hanover, NJ:Novartis Pharmaceuticals Corporation; 2000 Dec.
  • URSO package insert. Minneapolis, MN:Axcan Pharma US Inc; 1998 April
  • LAZARIDIS KN, GORES GJ, LINDOR KD: Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders.' Hepatol (2001) 35:134–146.
  • ••Very detailed description of possiblemechanisms for the efficacy of UDCA in liver diseases.
  • LAURIN J, LINDOR KD, CRIPPIN JS et al.: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology (1996) 23:1464–1467.
  • GUMA C, VILA L, THOME M, GALDAME 0, ALVAREZ E: Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: Results of a prospective clinical controlled trial (abstract). Hepatology (1997) 26:387A.
  • CERIANI R, BRUNATI S, MORINI L, SACCHI E, COLOMBO G: Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis (abstract). Hepatology (1998) 26:386A.
  • VAJRO P, FRANZESE A, VALERIO G, IANNUCCI MP, ARAGIONE N: Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. Pediatr. (2000) 136:739–743.
  • O'BRIEN CB, SENIOR JR, ARORA-MIRCHANDANI R, BATTA AK, SALEN G: Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30-month pilot study. Hepatology (1991) 14:838–847.
  • HARNOIS DM, ANGULO P, JORGENSEN RA, LARUSSO NE LINDOR KD: High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am. Gastroenterol (2001) 96:1558–1562.
  • BEUERS U, SPENGLER U, KRUIS W et al.: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology (1992) 16:707–714.
  • MITCHELL SA, BANSI DS, HUNT N, VON BERGMANN K, FLEMING KA, CHAPMAN RW: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology (2001) 121:900–907.
  • VAN HOOGSTRATEN HJF, WOLFHAGEN FHJ, VAN DE MEEBERG PC et al.: Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. I Hepatol (1998) 29:417–423.
  • LINDOR KD: Ursodiol for primary sclerosing cholangitis. N Engl. ./. Med. (1997) 336:691–695.
  • ••Largest study of ursodeoxycholic acid inPSC.

Websites

  • http://www.tripharm.com Triangle Pharmaceuticals, Inc. website [resource on World Wide Web]. Accessed 2002 April.
  • http://uptodateonline.com. Up to date® Home Page [resource on World Wide Web]. URL: Accessed 2002 February.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.